Overview

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Status:
NOT_YET_RECRUITING

Trial end date:
2029-12-01

Target enrollment:

Participant gender:

Summary

This study will treat patients with advanced NSCLC harboring EGFR mutations. This is the first study to test DZD6008 combined with sunvozertinib in patients, which will help to understand what type of side effects with the treatment. It will also measure the levels of two drugs in the body and preliminarily assess the anti-tumor activity with the combination treatment

Phase:

PHASE1

Details

Lead Sponsor:

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Treatments:

osimertinib